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Abstract
Resistant hypertension (RHTN) is a multifactorial disease 
characterized by blood pressure (BP) levels above goal 
(140/90 mmHg) in spite of the concurrent use of three or 
more antihypertensive drugs of different classes. Moreover, 
it is well known that RHTN subjects have high prevalence 
of left ventricular diastolic dysfunction (LVDD), which 
leads to increased risk of heart failure progression. This 
review gathers data from studies evaluating the effects of 
phosphodiesterase-5 (PDE-5) inhibitors (administration 
of acute sildenafil and short-term tadalafil) on diastolic 
function, biochemical and hemodynamic parameters in 
patients with RHTN. Acute study with sildenafil treatment 
found that inhibition of PDE-5 improved hemodynamic 
parameters and diastolic relaxation. In addition, short-term 
study with the use of tadalafil demonstrated improvement 
of LVDD, cGMP and BNP-32 levels, regardless of BP 
reduction. No endothelial function changes were observed 
in the studies. The findings of acute and short-term studies 
revealed potential therapeutic effects of IPDE-5 drugs on 
LVDD in RHTN patients.
Introduction
Resistant hypertension (RHTN) is a multifactorial 
condition characterized by blood pressure (BP) levels 
above goal (140/90 mmHg) in spite of the concurrent use 
of three or more antihypertensive drugs of different classes 
or controlled BP with the use of four or more agents1. The 
overall prevalence is estimated from 15% to 18% of all 
hypertensive individuals in population-based studies2,3 
and frequently the increasing number of antihypertensive 
drugs used in the course of disease1,4 is associated with 
with overweight or obesity and diabetes type 2; however, 
those conditions are not enough to primarily explain 
the individuals’ physical limitations and cardiovascular 
complaints. In an echocardiography study, it was observed 
that 95% of RHTN and 72% of controlled hypertensive 
subjects had left ventricular diastolic dysfunction (LVDD) 
with preserved systolic function5. 
Previous studies have demonstrated that hypertensive 
rat models produced by chronic treatment with nitric oxide 
(NO) inhibitor – NG-nitro-L-arginine methyl ester (L-NAME) 
– showed marked impairment of the first temporal derivative 
negative pressure of the LV diastolic pressure (-dP/dt, in 
mmHg/s), indicating LVDD in those animals 6, 7. Curiously, 
this effect was reversed by oral administration of sildenafil, 
a selective phosphodiesterase type 5 inhibitor (IPDE-5) 
after 8 weeks of treatment8. Indeed, immunohistochemistry 
revealed reduced L-NAME-related myocardial lesions, in 
addition to increased PDE-5 intensity in the intercalary 
discs between myocytes 9. Hence, this finding was related 
to improvement in LVDD due to direct sildenafil effect on 
cardiac relaxation in L-NAME-treated rats.
Therefore, because of the high prevalence of LVDD (95%) 
observed in our Outpatient Clinic specialized in RHTN 
(Campinas, Brazil) 5 and the lack of standard treatment, 
which reduces mortality rates 10, our group recently sought 
to investigate LVDD condition by echocardiography – a 
non-invasive diagnostic method frequently used – in 
association with IPDE-5 in acute (sildenafil) and short-term 
(tadalafil) administration. Thus, this clinical update report 
two recently published findings that evaluated the effects of 
PDE-5 inhibitors on diastolic function in the specific group 
of resistant hypertensive subjects 11, 12.
LVDD TREATMENT in RHTN: primary clinical studies 
using IPDE-5 drugs
Acute study
The hypothesis for the first recently published study 
involved a selective IPDE-5 and LVDD in RHTN patients, 
considering that acutely administered sildenafil could 
improve hemodynamic parameters, endothelial and left 
ventricular diastolic functions 11. This crossover, single-
blind and placebo-controlled study included 26 subjects 
diagnosed with RHTN (Clinicaltrial.gov - Protocol ID: CAAE-
0758.0.146.000-09). Endothelial function (assessed by 
flow-mediated dilation method-FMD) and echocardiogram 
were determined during pre and post-sildenafil treatment, 
as well as measures of nitrite and plasma cyclic guanosine 
monophosphate (cGMP) levels. Additionally, non-invasive 
hemodynamic parameters (Finometer - Finapres Medical 
Systems; Amsterdam, Netherlands) were evaluated prior to 
and during the entire period of sildenafil treatment, with 
increasing dose administration (37.5, 50 and 100 mg) at 
30-minute intervals.
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No differences were found in nitrite and cGMP 
levels, as well as in endothelial function after sildenafil 
use. Conversely, hemodynamic evaluation revealed that 
sildenafil administration contributed to the decrease in 
mean blood pressure (MAP) at increasing doses, when 
compared to baseline levels (84.17±21.04 to 75±17.21 
mmHg, p<0.05). Total peripheral resistance (TPR) 
was markedly reduced after the first dose of 37.5 mg 
(1149±459.7 to 1037±340 dyn.s/cm−5, p<0.05), but 
heart rate increased progressively with cumulative doses of 
this short-acting IPDE-5. Finally, improvement in diastolic 
function with reduction of: (1) left atrial volume (25.4±1.1 
to 20.9±0.9 mL, p<0.05), (2) isovolumetric relaxation 
time (104.4±3.8 to 88.3±3.0 ms, p<0.05), (3) E/e’ lateral 
and E/e’ septal ratios (7.7±0.7 to 6.4±0.6 and 9.8±0.8 to 
7.9±0.6, respectively, p<0.05) was found, when compared 
to pre-sildenafil echocardiogram.
The findings suggested that acute inhibition of PDE-5 
improves hemodynamic parameters – reducing MAP levels 
through TPR reduction – as well as diastolic relaxation, 
although endothelial function changes were not observed 11 .
Short-term study
In a second recently published study, our group 
investigated whether tadalafil use, a long-acting IPDE-5 
drug, improved LVDD in RHTN patients, regardless of 
BP reduction 12. A total of 19 patients were included in 
this crossover, single-blind and placebo-controlled study 
(ClinicalTrials.gov - Protocol ID: CAAE-0044.0.146.000-
09). All subjects received oral tadalafil (20 mg/day) for 
2 weeks. Endothelial (FMD method) and LV diastolic 
(echocardiography) functions, nitrite, plasma cGMP and 
B-type natriuretic peptide (BNP-32) levels were determined 
at baseline and post-tadalafil treatment.
No changes in endothelial function or nitrite levels 
were observed. On the other hand, cGMP increased and 
BNP-32 reduced after the use of tadalafil (62.4±32.2 to 
112.6±75.3 pmol/mL and143.3±33.3 to 119.3±31.3 pg/
mL, respectively, p<0.05). Echocardiography revealed 
improvement of the LVDD variables: (1) peak E-wave velocity 
(67.8±18.3 to 77.8±16.0 cm/s, p<0.05); (2) E/A ratio 
(0.9±0.3 to 1.08±0.3, p<0.05); (3) E-wave deceleration 
time (234.1±46.0 to 194.4±43.3 ms, p<0.05); (4) lateral 
E′-wave velocity (7.7±2.1 to 8.8±2.8 cm/s, p<0.05); (5) 
isovolumetric relaxation time (128.7±17.6 to 96.8±26.9 ms, 
p<0.05); and (6) both septal and lateral S′-wave velocities 
(6.3±1.4 to 7.7±1.7 and 7.5±2.3 to 8.3±2.2 cm/s, 
respectively, p<0.05) post-tadalafil treatment. Moreover, 
the study showed reductions in dyspnea, palpitations, and 
fatigue reported by the patients.
In summary, this short-term study demonstrated clinical 
relevance with the use of tadalafil for 2 weeks on LVDD 
treatment and diastolic function-related biomarkers in RHTN 
subjects, and this effect was independent of BP reduction 12.
Mechanism discussion
The findings of the acute study with increasing doses 
of sildenafil (37.5, 50 and 100 mg at 30-minute intervals) 
showed improvement in the hemodynamic profile and 
LVDD in RHTN patients.
Previously, studies have evaluated the administration 
of IPDE-5 inhibitor in hypertensive groups. Firstly, it was 
demonstrated that sildenafil use during 16 days reduced 
ambulatory BP levels in untreated hypertensive subjects 13. 
A second study has demonstrated BP reduction with acute 
sildenafil administration in a single dose (50 mg) in RHTN 
14. This study also found that the combination of sildenafil 
and organic nitrate (isosorbide mononitrate) was well 
tolerated and resulted in a greater decrease in brachial and 
central BP levels, raising the idea that this new therapeutic 
approach might be effective to RHTN patients. Despite 
these important findings, the mechanism of BP reduction 
was not reported. 
The proposal to investigate hemodynamic parameters 
continuously contributed to detect that BP reduction was 
due to TPR reduction, since cardiac output remained 
unaltered. Curiously, the marked decrease in MAP levels 
and TPR occurred after the first sildenafil dose (37.5 mg), 
which was not sustained with consecutive administration of 
increasing doses (50 mg and 100 mg). In accordance with 
previous studies 15, 16, those findings indicated that sildenafil 
did not have a dose-dependent effect 11.
The proposed causal mechanism for LVDD improvement 
in the acute study was also due to TPR reduction 11. Taken 
together, those findings suggest that LVDD is characterized 
by increased afterload – resulting from increased TPR – with 
myocardial relaxation impairment of the left ventricle. 
Hence, it contributes to resistance in ventricular filling and 
alterations of diastolic pressure/volume ratio17, 18 (figure 1).
The short-term study assessed the effects of long-acting 
IPDE-5 (tadalafil 20 mg/day for 2 weeks) and resulted in 
LVDD improvement, regardless of BP reduction, and in 
cGMP and BNP-32 alterations after drug use in RHTN 
subjects. However, no nitrite and endothelial function 
changes were observed 12. Those findings reinforced the 
hypothesis of the direct tadalafil effects on cardiomyocytes, 
as we could exclude the potential influence of NO-
mediated vasodilation, and consequently, reduction of 
ventricular afterload (TPR was not altered).
Previous studies have demonstrated that PDE-5, 
through cGMP signaling pathway, leads to adverse cardiac 
remodeling 19-22 and its inhibition – with increased levels of 
cGMP – results in positive effects, such as the blocking of 
adrenergic, hypertrophic and apoptotic signaling pathways 
23. In accordance with these clinical findings, a study 
demonstrated the increase in plasma cGMP levels and left 
ventricular diastolic and systolic capacitance and decrease 
in measurements of cardiomyocyte passive stiffness during 
serial treatment with sildenafil and with BNP 24. The PDE-
5 enzyme was found in the intercalary discs between 
myocytes and IPDE-5 may have a potential relevance for 
diastolic relaxation by preventing the L-NAME–induced 
impairment in -dP/dt measurement. Thus, attenuation of 
deleterious hemodynamic and morphological alterations 
observed with L-NAME treatment might be modulated by 
PDE5 inhibition in cardiac myocytes 9. In addition, IPDE-
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5 treatment may reduce cardiac inflammation followed 
by an improved remodeling process, as well as cardiac 
apoptosis, resulting in improved LV function in experimental 
models of angiotensin II-induced heart failure 25. These 
mechanisms highlight the importance of PDE-5 as a strategic 
pharmacological target for cardiomyocytes relaxation and, 
consequently, for LVDD improvement by increasing cGMP 
levels after treatment with IPDE-5 drugs.
Finally, the reduction of BNP-32 levels – a clinical 
biomarker widely used for diagnosis, prognosis, and 
treatment of heart failure 26 – in the short-term study 
revealed a close association with LVDD 12. Similarly to 
previous studies, which demonstrated that natriuretic 
peptides were strong predictors of diastolic dysfunction 27-
29, the short-term study suggested the potential diagnostic 
role in measuring BNP-32 levels to evaluate cardiovascular 
alterations related to LVDD (Figure 1).
Clinical Implications
Resistant hypertension is a chronic disease and several 
factors that contribute to a complex pathophysiology might 
differ among the subjects, which compromise the efficacy of 
therapeutic regimens. Hence, those many different mechanisms 
may result in greater difficulties to achieve BP control, even 
despite the use of multiple drugs with confirmed adherence, 
leading to resistance to antihypertensive treatment 30, 31. 
The challenge of RHTN treatment points out that the inclusion 
of new drugs is necessary to the therapeutic scheme of resistant 
hypertensive patients. In this context, recently IPDE-5 drugs 
were tested as antihypertensive treatment 13, 14. Moreover, due 
to the high prevalence of LVDD in RHTN subjects 5 – which 
is associated with worse outcomes 32 – and evidence from 
preclinical studies that have demonstrated diastolic function 
improvement 6, 24, IPDE-5 emerges as a highly promising 
candidate for the treatment of clinical conditions, such as LVDD, 
associated with resistance to antihypertensive therapy.
Some studies have sustained the hypothesis that IPDE-5 
drug use is a viable pharmacological strategy for improvement 
in LV relaxation due to (1) shortening in both lateral and septal 
T E-E´(a Doppler-derived index of LV relaxation performance) 
33; (2) the reverse cardiac remodeling effect; and (3) the 
reduced levels of BNP precursor over time 34. LVDD treatment 
in RHTN population is important because LVDD does not 
have a standard treatment, therefore the use of therapeutic 
candidates could reduce mortality, especially in resistant 
hypertensive subjects, who have high cardiovascular risk35.
Figure 1 – Potential mechanisms for the improvement of left ventricular diastolic dysfunction in preclinical and clinical studies.
Pre-clinical studies
L-NAME treated rats
Clinical studies in 
RHTN
Left ventricular diastolic 
dysfunction
Cardiomyocytes
Sildenafil treatment – 8 weeks
(45mg/Kg/day)
• Prevented the reduction of diastolic relaxation 
(-dP/dt)
• Increased PDE5 intensity
• Reduced cardiovascular remodelling
Reduction of TPR
• Reduced LV afterload;
• Improvement of diastolic relaxation, LV filling 
and diastolic pressure/volume relation;
• Decreased left atrial volume, isovolumetric 
relaxation time and E/e’ lateral and E/e’ septal 
ratios
Sildenafil acute study
(37.5/50/100 mg)
Tadalafil short-time study
( 20 mg/day - 2 weeks)
Direct effects on cardiomyocytes
• Improvement of the peak E-wave velocity, E/A 
ratio, E-wave deceleration time, lateral E’ –wave 
velocity, isovolumetric relaxation time and both 
septal and lateral S’-wave velocities
• Increased GMPc and reduced BNP-32 levels
87
Review Article
Faria et al.
PDE-5 inhibitors in difficult-to-treat hypertension
Arq Bras Cardiol. 2015; 104(1):85-89
Recent studies, including the acute study from 
our group11, have shown BP reduction after sildenafil 
administration14,26. This effect must be carefully interpreted. 
Although those studies may point out to a meaningful 
clinical effect on BP, we must consider that they were 
conducted in a short period of time, not allowing us to 
conclude that a chronic treatment would have the same 
impact on BP levels.
Finally, both acute and short period administration of 
IPDE-5 drugs (sildenafil and tadalafil, respectively) were well 
tolerated according to patient self-reports. This may represent 
a great clinical advantage, especially when treating RHTN 
subjects, since those patients are taking multiple drugs and 
the adverse effects are relevant for treatment adherence 36.
The results of the abovementioned acute and short-
term studies contributed to advance our knowledge about 
potential therapeutic effects of IPDE-5 drugs on LVDD in 
RHTN patients. As we did not investigate drug action in the 
long term, those findings reinforce that future prospective 
clinical studies must be conducted to evaluate efficacy and 
safety of IPDE-5 candidates in treatment of LVDD using a 
larger RHTN population in a long-term trial.
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